Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 14, 2007
Event Date: June 11, 2007
Context: Emergent BioDefense Operations Lansing Inc., a wholly owned subsidiary, entered into a material definitive agreement involving a new line of credit.
Key Financial Metrics and Obligations
This filing details a specific financing arrangement rather than periodic financial performance metrics (revenue, profit, cash flow). Key terms of the new obligation include:
- Facility Type: Revolving line of credit.
- Maximum Amount: $15.0 million.
- Maturity Date: May 15, 2008.
- Interest Rate: Prime rate minus 0.375%, payable monthly.
- Collateral: Secured by accounts receivable from U.S. Department of Defense and U.S. Department of Health and Human Services contracts for BioThrax®.
- Borrowing Limit: Outstanding principal cannot exceed 75% of eligible accounts receivable.
- Eligibility Criteria: Accounts receivable must not be older than 90 days from the invoice date or shipment/performance date.
Material Changes and Covenants
The filing reports the creation of a direct financial obligation. The agreement includes standard affirmative and negative covenants. Negative covenants restrict the subsidiary from:
- Incurring additional indebtedness or liens.
- Selling assets.
- Making loans, advances, or guarantees.
- Entering into mergers or similar transactions.
- Entering into transactions with affiliates.
- Amending terms of Government Contracts.
Risks, Contingencies, and Events of Default
Payment obligations may be accelerated upon an event of default. Defined events of default include:
- Payment defaults or failure to perform obligations.
- Failure to comply with covenants.
- Default on other indebtedness exceeding $250,000 that allows acceleration.
- Inaccuracy of representations and warranties.
- Termination of any guarantee.
- Material failure to perform or termination of Government Contracts (other than by expiration).
- Court or governmental orders preventing the sale of BioThrax®.
- Bankruptcy and insolvency related defaults.
Note: The filing text does not provide specific revenue, profit, or liquidity figures for the reporting period, nor does it contain forward-looking guidance or management commentary beyond the terms of the loan agreement.
Investor Verification Checklist
- Verify the current status and aging of accounts receivable under Government Contracts to assess borrowing capacity.
- Confirm the current prime rate to calculate the effective interest cost.
- Review the terms of the underlying BioThrax® supply contracts with the DoD and HHS for stability and performance risks.
- Monitor compliance with negative covenants regarding asset sales and additional indebtedness.
- Assess the impact of the $15.0 million facility on the company's overall leverage and liquidity position.